Replicate Bio and Novo Nordisk collaborate on srRNA therapies

Replicate Bioscience and Novo Nordisk have partnered to develop self-replicating RNA (srRNA) therapies for obesity and diabetes. Novo Nordisk will obtain a global license to use Replicate’s srRNA platform, providing up to $550 million in research funding, including milestone payments. The collaboration aims to innovate treatments for cardiometabolic diseases, leveraging Replicate's technology and Novo Nordisk's drug development expertise. Replicate's srRNA platform promises enhanced protein expression and durability, with ongoing projects in infectious disease and immunology.